Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2023 Results Conference Call May 3, 2023 4:30 PM ET

Company Participants

Lisa Miller - Senior Director, IR

Rick Hawkins - CEO & Chairman

Lori Lawley - CFO & Principal Accounting Officer

David Karpf - Chief Medical Officer

John McKew - Chief Scientific Officer & President

Conference Call Participants

Catherine Novack - Jones Trading

Charles Duncan - Cantor Fitzgerald

Leland Gershell - Oppenheimer

Ed White - H.C. Wainwright & Co

Yasmeen Rahimi - Piper Sandler

Operator

Good afternoon, and welcome to Lumos Pharma's Q1 2023 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded.

I'll now turn the call over to Lisa Miller, Senior Director of Investor Relations.

Lisa Miller

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release we issued this afternoon, and in our Form 10-Q, which may be accessed from the Investors page of the company's website.

Speaking on today's call will be Rick Hawkins, CEO, and Chairman; and Lori Lawley, our CFO; John McKew, our President and Chief Scientific Officer; and David Karpf, our Chief Medical Officer, will join for question-and-answer session.

I will now turn the call over to Rick.

Rick Hawkins

Thank you, Lisa, and good afternoon, everyone. And after the market closed today, we issued a press release announcing our first quarter 2023 financial results and providing an update on our clinical programs. As is our practice, we'll keep our prepared remarks on today's call brief, so we can maximize the time available for Q&A. I'll touch on some of the highlights from the quarter in recent weeks before turning it over to Lori for a review of our financial results. And John McKew and David Karpf will join us to answer your questions. So, let's begin.

As we reported this afternoon, during the first quarter of 2023, we made significant progress and advancing our oral therapeutic candidate LUM-201 in Idiopathic Pediatric Growth Hormone Deficiency, led by the completion of patient enrollment, and both our phase II OraGrowtH210 and OraGrowtH212 trials. And we can confirm our expectation to report primary outcome battle on the 82 subjects in the dose range finding OraGrowtH210 trial, and up to 22 subjects in the PK/PD OraGrowtH212 trial in the fourth quarter of 2023.